{
  "ticker": "ILA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967683",
  "id": "02967683",
  "pages": 6,
  "price_sensitive": true,
  "date": "20250709",
  "time": "0916",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06lmmyp3mdr0s8.pdf",
  "summary": "### **Material Information Summary**  \n\n#### **Strategic Acquisition Announcement**  \n- **Acquisition:** Galidesivir antiviral program from BioCryst Pharmaceuticals (Nasdaq: BCRX).  \n- **Consideration:**  \n  - **Upfront payment:** US$550,000 (includes US$50,000 option fee).  \n  - **Milestones:**  \n    - US$500,000 upon Phase 2 completion.  \n    - US$1M (standard approval) or US$1.5M (Animal Rule approval).  \n    - Royalties: 5-10% of net sales.  \n    - 25% of Priority Review Voucher (PRV) proceeds if awarded.  \n- **Regulatory Pathway:** FDA **Animal Rule** potential \u2013 may require only **one additional Marburg animal study** for New Drug Application (NDA).  \n- **PRV Potential:** Approval could grant a **PRV** (recent sales: US$100\u2013150M).  \n- **Funding:** Existing cash (AUD **$4.82M** as of 30 April 2025 + **$3.6M** placement).  \n- **Next Steps:** Maiden animal study in Marburg within **12 months**.  \n\n**Key Catalyst:** FDA engagement on Animal Rule pathway and PRV eligibility.  \n\n*(Omitted: Background on PRVs, team bios, webinar details.)*",
  "usage": {
    "prompt_tokens": 3933,
    "completion_tokens": 292,
    "total_tokens": 4225,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-08T23:42:57.394637"
}